Merck Sharp & Dohme 8-K Merck Reports Strong Financial Results for First-Quarter 2007

Exhibit 99.2

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
FIRST QUARTER
2007

EQUITY INCOME FROM AFFILIATES (millions of dollars)

	1Q `07			1Q `06
MERCK / SCHERING-PLOUGH	$	(347.2	)	$	(188.0	)
ASTRAZENECA LP		(211.9	)		(213.5	)
Other (1)		(93.5	)		(101.9	)
TOTAL	$	(652.6	)	$	(503.4	)

⁽¹⁾ Primarily reflects results for Merial Limited, and joint ventures with Sanofi Pasteur and Johnson & Johnson.

JOINT VENTURE SALES DETAIL (millions of dollars)

All sales reported here are end-market JV sales, presented on a “NET” basis.

Merial	1Q `07		1Q `06
IVOMEC, HEARTGARD, other avermectins	$	137.4	$	129.5
FRONTLINE		327.6		261.5
BIOLOGICALS		153.3		139.5
Other Animal Health		59.4		55.2
TOTAL MERIAL SALES	$	677.7	$	585.7

Sanofi Pasteur-MSD	1Q `07		1Q `06
HEPATITIS VACCINES	$	16.7	$	19.1
VIRAL VACCINES		20.1		21.7
Other Vaccines(1)		158.0		131.9
TOTAL SANOFI-MSD SALES	$	194.8	$	172.7

⁽¹⁾ Includes $30.2 million for Gardasil in 1Q07.

Merck / Schering-Plough Collaboration	1Q `07		1Q `06
VYTORIN	$	623.8	$	378.4
ZETIA		544.0		414.8
TOTAL MERCK / SCHERING-PLOUGH SALES	$	1,167.8	$	793.2

OTHER (INCOME) EXPENSE, NET (millions of dollars)

	1Q `07			1Q `06
INTEREST INCOME	$	(181.7	)	$	(181.7	)
INTEREST EXPENSE		102.4			98.2
EXCHANGE GAINS		(19.6	)		(0.4	)
MINORITY INTERESTS		30.6			29.9
Other, net		(187.7	)		(46.6	)
TOTAL	$	(256.0	)	$	(100.6	)

Exhibit 99.2

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
FIRST QUARTER
2007

NET PRODUCT SALES DETAIL (millions of dollars)

	1Q `07 vs. 1Q `06
	TOTAL			TOTAL		U.S.			U.S.		Foreign			Foreign
PRODUCT	% CHG			$		% CHG			$		% CHG			$
COZAAR / HYZAAR		14	%		798		32	%		305		5	%		493
FOSAMAX		-2	%		742		6	%		483		-13	%		259
SINGULAIR		25	%		1,002		23	%		710		30	%		292
ZOCOR		-76	%		258		-92	%		70		-18	%		188
Vaccines:
GARDASIL		*			365		*			312		*			53
ROTATEQ		*			85		*			82		*			3
ZOSTAVAX		*			43		*			43		N/A			—
OTHER VIRAL VACCINES(1)		55	%		246		70	%		227		-25	%		19
HEPATITIS VACCINES		34	%		72		45	%		60		-4	%		12
OTHER VACCINES		63	%		92		61	%		66		68	%		26
Other Reported Products:
AGGRASTAT		7	%		24		N/A			—		7	%		24
ARCOXIA		35	%		80		N/A			—		35	%		80
CANCIDAS		-8	%		134		-51	%		38		40	%		96
COSOPT / TRUSOPT		23	%		186		45	%		83		9	%		103
CRIXIVAN / STOCRIN		1	%		82		-14	%		6		2	%		76
EMEND		*			48		*			36		*			12
INVANZ		47	%		42		40	%		23		56	%		19
JANUVIA		*			87		*			83		*			4
MAXALT		16	%		107		22	%		71		5	%		37
PRIMAXIN		16	%		197		21	%		61		14	%		136
PROPECIA		27	%		95		7	%		37		43	%		59
PROSCAR		-33	%		125		-73	%		26		8	%		99
TIMOPTIC / TIMOPTIC XE		-5	%		29		-7	%		2		-5	%		27
VASOTEC / VASERETIC		-11	%		122		N/A			—		-11	%		122
ZOLINZA		*			2		*			2		N/A			—

* 100% or over

N/A – Not Applicable

⁽¹⁾ – Includes ProQuad, M-M-R II and Varivax.

TOTAL SALES: VOLUME, PRICE, EXCHANGE

	1Q '07		% CHG.			VOL		PX		FX
TOTAL PHARMACEUTICAL SALES	$	5,769		7	%		6		—		1
U.S. ($ MM)		3,505		8	%		7		1		N/A
Foreign ($ MM)		2,264		5	%		4		-3		4